Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003.
about
Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortalityOsteoprotegerin levels in patients with severe mental disordersRoles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular DiseaseCirculating osteoprotegerin is associated with chronic kidney disease in hypertensive patientsCorrelates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney diseaseCorrelation of increased plasma osteoprotegerin and cardiovascular risk factors in patients with adult growth hormone deficiency.Premature atherosclerosis in children with beta-thalassemia major: New diagnostic marker.Correlation of plasma osteoprotegerin (OPG) and receptor activator of the nuclear factor κB ligand (RANKL) levels with clinical risk factors in patients with advanced carotid atherosclerosis.Osteoprotegerin as a marker of atherosclerosis in diabetic patients.Cardiovascular diseases in older patients with osteoporotic hip fracture: prevalence, disturbances in mineral and bone metabolism, and bidirectional linksTreating inflammation in atherosclerotic cardiovascular disease: emerging therapies.The role of osteoprotegerin (OPG) receptor activator for nuclear factor kappaB ligand (RANKL) in cardiovascular pathology - a review.The role of osteoprotegerin in cardiovascular disease.Prediction of Fractures and Major Cardiovascular Events in Men Using Serum Osteoprotegerin Levels: The Prospective STRAMBO Study.Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus.Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromsø Study.Dyslipidemia and Diabetes Increase the OPG/TRAIL Ratio in the Cardiovascular System.Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: Literature-based meta-analysis involving 26,442 participants.Associations of osteoprotegerin with coronary artery calcification among women with systemic lupus erythematosus and healthy controls.Investigation of OPG/RANK/RANKL Genes as a Genetic Marker for Cardiac abnormalities in Thalassemia Major Patients.Osteoprotegerin/sRANKL Signaling System in Pulmonary Sarcoidosis: A Bronchoalveolar Lavage Study.Osteoprotegerin, but not osteopontin, as a potential predictor of vascular calcification in normotensive subjects.Circulating osteogenic proteins are associated with coronary artery calcification and increase after myocardial infarction
P2860
Q24623768-37073B61-3A92-4F1D-A4DB-E81120F2654AQ24626094-24111346-777B-4729-A31D-496AC058706CQ26747224-728E25C7-273C-40F4-B17D-EB25CEEAC5E3Q33882341-F5CDF062-505E-4759-B288-0664ADBE53B9Q34028264-0AAE293F-EC20-44CB-BCAB-5F2962D069F4Q35643468-813252BE-3E59-465A-9079-9C4F753D8D1BQ36303189-F372329A-7471-46B3-8852-55CC11F8DD2EQ36576768-734C46D9-37B1-4131-8E86-1D9871C788D7Q36582644-71800840-3BFA-4EF0-9574-43B8BDFD3FC5Q36648170-B5100E80-74A5-46F8-A974-F423FF5D9B98Q37625670-ED6BB6AF-B0ED-436F-81AA-5CBB4EB0AE81Q37922640-F8009669-E117-4BD7-9B20-3EA13C3B87D2Q38056541-1E952FD2-98CE-404A-9303-709CFAA30B33Q38693577-6DA29034-C958-4B28-AFC3-95EA89C65FADQ39197051-37FE48F7-5C9D-4296-8317-429384665491Q39787548-DDFC628F-2713-4BA4-A5F8-097F4DAD27C6Q40041063-E46CBBFB-602E-4F13-9E0D-90B44F63F5BAQ41513500-18F924E0-51D3-4FC3-A65A-156F5678A63DQ50135771-30F9B2A9-32ED-4011-997F-C9B6E8AD5D29Q51119015-CBB22E18-749B-4C12-AF19-7A2031EE6F5CQ51337112-B5188B12-4435-49D8-93CE-4CAC9E5FEDA1Q53178524-FB15C004-778E-441A-959D-B83C989DC7FCQ58715301-92955BF5-861C-4603-9017-6618B4ED9CBC
P2860
Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Osteoprotegerin and soluble re ...... lk population study 1993-2003.
@en
Osteoprotegerin and soluble re ...... lk population study 1993-2003.
@nl
type
label
Osteoprotegerin and soluble re ...... lk population study 1993-2003.
@en
Osteoprotegerin and soluble re ...... lk population study 1993-2003.
@nl
prefLabel
Osteoprotegerin and soluble re ...... lk population study 1993-2003.
@en
Osteoprotegerin and soluble re ...... lk population study 1993-2003.
@nl
P2093
P50
P1476
Osteoprotegerin and soluble re ...... lk population study 1993-2003.
@en
P2093
Anne G Semb
John J P Kastelein
S Matthijs Boekholdt
P304
P356
10.1161/ATVBAHA.109.184101
P407
P577
2009-03-26T00:00:00Z